**Supplementary Table 1. Characteristics according to line of therapy in Child-Pugh A group**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **First line (n=57)** | **Second or later lines (n=17)** | ***p*-value** |
| **Age, years, mean±SD** | 60.3 ± 11.0 | 57.7 ± 8.6 | 0.385 |
| **Gender, male** | 47 (82.5%) | 11 (64.7%) | 0.119 |
| **Etiology**  |  |  | 0.282 |
|  Hepatitis B | 37 (64.9%) | 14 (82.4%) |  |
|  Hepatitis C | 10 (17.5%) | 0 |  |
|  Alcohol | 5 (8.8%) | 1 (5.9%) |  |
|  Unknown | 5 (8.8%) | 2 (11.8%) |  |
| **BCLC stage, B/C** |  |  | 0.810 |
|  B | 8 (14.0%) | 2 (11.8%) |  |
|  C | 49 (86.0%) | 18 (88.2%) |  |
| **Tumor extent**  |  |  |  |
| Extrahepatic metastasis  | 34 (59.6%) | 14 (82.4%) | 0.146 |
| Macrovascular invasion | 20 (35.1%) | 10 (58.8%) | 0.080 |
| Main portal vein invasion | 9 (15.8%) | 4 (23.5%) | 0.480 |
| Bile duct invasion | 4 (7.0%) | 2 (11.8%) | 0.616 |
| Tumor occupying ≥ 50% of the liver | 15 (26.3%) | 2 (11.8%) | 0.327 |
| **Baseline serum alpha fetoprotein > 200 ng/ml**  | 26 (45.6%) | 11 (64.7%) | 0.167 |
| **Maximum intrahepatic tumor size (mm), mean±SD** | 54 ± 49 | 46 ± 33 | 0.510 |
| **Subsequent treatment after lenvatinib** | 23 (56.1%) | 5 (33.3%) | 0.227 |

SD; standard deviation, BCLC; Barcelona Clinic Liver Cancer

**Supplementary Table 2. Characteristics patients according to subsequent treatment after lenvatinib**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Subsequent treatment, yes****(n=32)** | **Subsequent treatment, no****(n=27)** | ***p*-value** |
| **Age, years, mean±SD** | 57.6 ± 12.4 | 59.0 ± 10.8 | 0.647 |
| **Gender, male** | 22 (68.8%) | 21 (77.8%) | 0.437 |
| **Etiology**  |  |  | 0.832 |
|  Hepatitis B | 23 (71.9%) | 21 (77.8%) |  |
|  Hepatitis C | 3 (9.4%) | 3 (11.1%) |  |
|  Alcohol | 3 (9.4%) | 1 (3.7%) |  |
|  Unknown | 3 (9.4%) | 2 (7.4%) |  |
| **BCLC stage, B/C** |  |  | 0.362 |
|  B | 4 (12.5%) | 1 (3.7%) |  |
|  C | 28 (87.5%) | 26 (96.3%) |  |
| **Child-Pugh class** |  |  | 0.035 |
|  A | 28 (87.5%) | 17 (63.0%) |  |
|  B | 4 (12.5%) | 10 (37.0%) |  |
| **Tumor extent**  |  |  |  |
| Extrahepatic metastasis  | 20 (62.5%) | 19 (70.4%) | 0.525 |
| Macrovascular invasion | 11 (34.4%) | 14 (51.9%) | 0.176 |
| Main portal vein invasion | 4 (12.5%) | 7 (25.9%) | 0.315 |
| Bile duct invasion | 2 (6.3%) | 7 (25.9%) | 0.066 |
| Tumor occupying ≥ 50% of the liver | 6 (18.8%) | 9 (33.3%) | 0.200 |
| **Baseline serum alpha fetoprotein > 200 ng/ml**  | 19 (59.4%) | 18 (66.7%) | 0.564 |
| **Maximum intrahepatic tumor size (mm), mean±SD** | 44 ± 40 | 74 ± 53 | 0.018 |

SD; standard deviation, BCLC; Barcelona Clinic Liver Cancer